Pure Global
NCT06320041

Efficacy and Safety of Oliceridine for Moderate to Severe Acute Pain After Orthopedic Surgery

The Fourth Affiliated Hospital of Zhejiang University School of Medicine·Phase 4·ClinicalTrials.gov·drugNot yet recruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Postoperative Pain
Drug/Device/Intervention
Low dose oxelidine group
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
The Fourth Affiliated Hospital of Zhejiang University School of Medicine
Timeline & enrollment
Phase
Phase 4
Start date
Apr 01, 2024
End date
Dec 31, 2024
Enrollment
162 participants
Primary outcome

Pain score at rest 0-72 hours after surgery

Summary

The goal of this clinical trial] is to further explore the effectiveness and safety of
 oxelidine in the treatment of moderate to severe acute pain after orthopedic surgery. The
 main question it aims to answer is: Pain management after orthopaedic surgery provides more
 effective and safe drug options, provides new options for clinical treatment, and provides a
 scientific basis for clinical practice.
 
 Participants will be asked to pain score in the different time, treatments they'll be given
 and use optimal drug. Researchers will compare analgesic effect of oxelidine of different
 dose.

ICD-10 classifications
Acute painPostoperative intestinal obstructionPain, unspecifiedDuring surgical operationDuring surgical operation
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06320041
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06320041 through Pure Global AI's free database. This Phase 4 trial is sponsored by The Fourth Affiliated Hospital of Zhejiang University School of Medicine and is currently Not yet recruiting. The study focuses on Postoperative Pain. Target enrollment is 162 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.